<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02509091</url>
  </required_header>
  <id_info>
    <org_study_id>20150616</org_study_id>
    <nct_id>NCT02509091</nct_id>
  </id_info>
  <brief_title>Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis</brief_title>
  <official_title>Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis:An Open-label Randomized Parallel Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The therapy of bronchoalveolar lavage and local amikacin injection as one of the treatment of
      bronchiectasis developed in recent years.this study is aim to evaluate the Clinical Efficacy
      and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients with
      Acute Exacerbation of Bronchiectasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study was to evaluate the efficacy and safety of The therapy of
      bronchoalveolar lavage and local amikacin injection through the observation of a large sample
      of clinical cases. During the observation, study visits will occur at the end of 30days,
      60days, 90days.all the participants will be required to check the various efficacy and safety
      indicators.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of Sputum volume and properties</measure>
    <time_frame>90 days</time_frame>
    <description>Phlegm improvement will be measured by the reduction of the sputum volume and change of sputum properties in the first day,in admission,the first day before,in and after doing bronchoscopy ,the day in discharge and in 30 days/60 days/90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in lung function (including Forced expiratory volume in one second (FEV1) ,forced vital capacity(FVC) and forced vital capacity rate of one second(FEV1/FVC))</measure>
    <time_frame>90 days</time_frame>
    <description>Lung function will be measured as improved/stabilized/exacerbated from baseline to 30 days/60 days/90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score according by Modified Medical Research Center(MMRC)</measure>
    <time_frame>90 days</time_frame>
    <description>to measure rating dyspnea according by Medi Medical Research Center(MMRC) from baseline to 30 days/60 days/90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough score according by Leicester Cough Questionnaire(LCQ)</measure>
    <time_frame>90 days</time_frame>
    <description>to measure rating cough according by Leicester Cough Questionnaire(LCQ) from baseline to 30 days/60 days/90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality: assessed by St. George respiratory questionnaire (SGRQ)</measure>
    <time_frame>90 days</time_frame>
    <description>Life quality will be assessed as improved if SGRQ single or total score increased &gt;4% when completing the trial; stabilized if SGRQ single or total score changes within the range of 4% when completing the trial; exacerbated if SGRQ single or total score decreased &gt;4% when completing the trial from baseline to 30 days/60 days/90 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>The experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fundamental treatment combining with the therapy of bronchoalveolar lavage and local Amikacin injection.(fundamental treatment including anti-infection,eliminating phlegm,oxygen therapy etc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The controlled group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>fundamental treatment(including anti-infection,eliminating phlegm,oxygen therapy etc.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchoalveolar Lavage and Local Amikacin Injection</intervention_name>
    <description>injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.</description>
    <arm_group_label>The experimental group</arm_group_label>
    <other_name>Amikin;AMK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≥18 years and ≤80 years;

          2. Patients with non-cystic fibrosis bronchiectasis diagnosed by high-resolution CT;

          3. Are sensitive to amikacin;

          4. Acute exacerbation of bronchiectasis;

          5. Capable of the completion of bronchoscopy, alveolar lavage, pulmonary function testing
             etc;

          6. Willing to join in and sign the informed consent form.

        Exclusion Criteria:

          1. Active bleeding without control；

          2. Receiving nasal or facial surgery recently；

          3. With severe cardio-pulmonary dysfunction, such as left heart failure, unstable
             arrhythmia, etc.

          4. With other respiratory diseases: such as active pulmonary tuberculosis,
             non-tuberculosis mycobacteria (NTM) pulmonary disease, pulmonary aspergillosis, etc.

          5. Be allergic to amikacin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Fu Xu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin-Fu Xu, MD</last_name>
    <phone>+86 13321922898</phone>
    <email>13321922898@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ke Fei</last_name>
      <phone>+86 21 65115006</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2015</study_first_posted>
  <last_update_submitted>May 13, 2016</last_update_submitted>
  <last_update_submitted_qc>May 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>Director, Head of respiratory medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

